ANL

Adlai Nortye Ltd

Add to Watchlist

Advanced Chart

1.610

+0.05(3.205%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.675

Open

1.620

VWAP

1.64

Vol

1.46K

Mkt Cap

59.41M

Low

1.610

Amount

2.40K

EV/EBITDA(TTM)

Total Shares

36.90M

23.88M

EV/OCF(TTM)

P/S(TTM)

Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.

1 Analyst Rating

459.01% Upside

Wall Street analysts forecast ANL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

459.01% Upside

Current: 1.610

Low

9.00

Averages

9.00

High

9.00

459.01% Upside

Current: 1.610

Low

9.00

Averages

9.00

High

9.00

H.C. Wainwright

Buy -> Neutral

downgrade

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Adlai Nortye to Neutral from Buy.

H.C. Wainwright

Joseph Pantginis

Buy -> Neutral

downgrade

2025-06-02

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

2025-06-02

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded Adlai Nortye to Neutral from Buy and removing its prior $9 price target on the shares after the company recently announced that the Phase 3 BURAN trial evaluating its lead asset buparlisib in combination with paclitaxel for the treatment of advanced HNSCC did not meet the primary endpoint of improving overall survival compared to paclitaxel alone. With these "disappointing" results and the "unfortunate" pivotal miss, the company has decided to discontinue advancement of the buparlisib program and intends to refocus resources on the advancement of two preclinical assets, AN8025 and AN9025, the analyst noted. Given the early stage nature of the remainder of the Adlai pipeline, the firm is downgrading shares as it awaits future clinical updates, the analyst explains.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-11-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-11-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-10-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-10-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Initiates

2024-09-04

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-09-04

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Adlai Nortye Ltd (ANL.O) is -4.65, compared to its 5-year average forward P/E of -4.24. For a more detailed relative valuation and DCF analysis to assess Adlai Nortye Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.24

Current PE

-4.65

Overvalued PE

-1.94

Undervalued PE

-6.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.30

Current EV/EBITDA

-0.64

Overvalued EV/EBITDA

1.56

Undervalued EV/EBITDA

-4.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.26

Current PS

0.00

Overvalued PS

5.56

Undervalued PS

-5.05